Merrimack Pharmaceuticals, Inc. (MACK) Social Stream



Merrimack Pharmaceuticals, Inc. (MACK): $5.83

-0.12 (-2.02%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MACK to Watchlist
Sign Up

Industry: Biotech


Ranked

of 495

in industry

Featured Post From StockTwits About MACK

$MACK On July 29, 2021, as part of its H1 2021 Results Presentation, Ipsen
provided to the public an update on the RESILIENT trial of ONIVYDE as a
second line treatment for Small Cell Lung Cancer, indicating that
clinical data from this trial as well as a possible regulatory filing are
anticipated in 2022. Ipsen also provided an update on the NAPOLI 3 trial
of ONIVYDE as a first line treatment for pancreatic cancer. Enrollment is
continuing in this trial and Ipsen indicated that clinical data as well
as a possible regulatory filing are expected in 2023
WVU1988, published August 5, 2021

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7993 seconds.